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Abstract
Background: Appropriate prescription of dabigatran etexilate methanesulfonate (JAN) is more complicated than
assumed, because there are totally 10 items of contraindications and instructions for dosage reduction depending
on patients’ characteristics. We aimed to study whether the routine audit of first-time prescriptions of dabigatran
performed by pharmacists is effective in improving the quality of prescription.
Methods: A retrospective re-audit was performed on all the prescriptions of dabigatran issued at Kitahara International
Hospital, Tokyo between March 2011 and February 2014, by evaluating the prescriptions rigorously against the
approved prescribing information of the drug. The original routine audit of the prescriptions for inpatients was
performed by hospital pharmacists using electronic medical records (EMR), whereas the audit for ambulant
patients receiving external prescriptions was performed by community pharmacists using information obtained
mainly by questioning patients. The frequencies of inappropriate prescriptions detected by the re-audit in the
two groups were compared.
Results: Two hundred and twenty-eight patients (131 ambulant patients and 97 inpatients) were prescribed dabigatran
for the first time during the study period. All patients met the approved indications. While 33% of the prescriptions for
ambulant patients showed at least one violation of the approved usage, only 11% of the prescriptions for inpatients
showed violations (p < 0.001). Two ambulant patients with creatinine clearance < 30 mL/min were dispensed
dabigatran, whereas no such case was found among inpatients. A significantly greater proportion of ambulant
patients aged ≥70 years showed violation of the instruction for dosage reduction compared to inpatients of the
same age group (18 and 4%, respectively).
Conclusion: The present study suggests that pharmacists may achieve better performance in auditing prescriptions
of dabigatran when medical records are fully available than when information is available mainly by questioning
patients. Further large-scale studies are required to clarify whether the audit of dabigatran prescriptions improves
ultimate therapeutic outcomes or complications.
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Background
Dabigatran etexilate methanesulfonate (JAN) is the first
direct oral anticoagulant (DOAC) launched in Japan for
preventing thromboembolic complications in patients
with non-valvular atrial fibrillation [1]. In contrast to
warfarin, a vitamin K antagonist, the anticoagulation
effect of dabigatran is not influenced by the variability of
oral vitamin K intake, drug interaction with cytochrome
P-450 (CYP) inhibitors, or genetic polymorphisms of
CYP2C9 [2]. In addition, there is no need for routine
monitoring with anticoagulation tests [1]. In this con-
text, prescribing dabigatran may appear less complicated
compared to warfarin. However, there are 6 items of
contraindications and 4 items of instructions for dosage
reduction in the prescribing information for dabigatran
in Japan [1]. As a result, inappropriate prescriptions that
violate the approved usage of the drug may not be un-
common, particularly in first-time prescriptions. To our
knowledge, however, no attempts have been undertaken
to study the frequency of inappropriate dabigatran pre-
scriptions in Japan.
Previous studies performed in the USA and European
countries have demonstrated that prescription audit by
pharmacists may reduce the incidence of potentially in-
appropriate prescriptions and improve medication safety
and patients’ adherence to pharmacotherapy, ultimately
improving patients’ quality of life [3–5]. While many re-
ports have documented the statistics of medication errors
for any drugs in Japan and the impact of pharmacists’
intervention on preventing these errors [6, 7], it remains
largely unclear whether prescription audit performed by
pharmacists may reduce inappropriate prescriptions of
DOACs. In our hospital, prescriptions of all drugs issued
to inpatients are subject to pharmacists’ audit using elec-
tronic medical records (EMR), and any potential violation
of prescribing instructions is fed back to the responsible
physician, and revision is made whenever necessary. In
contrast, external prescriptions are issued to ambulant
patients according to the national policy of the separation
of dispensary from medical practice. As a result, audit of
dabigatran prescription is performed by community phar-
macists using information obtained mainly by questioning
the patients. Given this situation, we aimed to study the
frequency of inappropriate dabigatran prescriptions, par-
ticularly for first-time prescriptions, and to study whether
audit of prescriptions by pharmacists using EMR rather
than questioning patients may improve the quality of
dabigatran prescription, particularly at the initiation of
anticoagulation therapy.
Methods
The present study was a retrospective observational
study performed at Kitahara International Hospital
(KIH), Hachioji, Japan. We reviewed the medical records
of all patients who started dabigatran therapy either as
inpatient after admission to our hospital or as ambulant
patient at the ambulant clinic of KIH between March
2011 and February 2014. We excluded patients who had
been initiated dabigatran therapy elsewhere before they
were referred to our hospital.
Before dabigatran was added to the drug formulary at
KIH, pharmacists organized an educational meeting for
all physicians who were going to prescribe the drug, re-
garding proper usage of the drug with respect to dosage
individualization in patients with renal dysfunction and
drug interaction with concomitantly administered drugs.
Regarding the assessment of renal function, estimated
glomerular filtration rate (eGFR) was automatically cal-
culated according to the MDRD equation modified for
Japanese by the Japanese Society of Nephrology with a
built-in function of the EMR [8]. In contrast, physicians
had to calculate creatinine clearance (CLcr) by them-
selves using the Cockcroft-Gault’s nomogram.
Routine audit of dabigatran prescriptions for inpatients
was performed by hospital pharmacists according to a
checklist (Table 1). The checklist is compatible with the
documents in the authorized prescribing information of
Prazaxa® [1], except for the instructions for switching
anticoagulation therapy from a parenteral anticoagulant
(e.g., unfractionated heparin) to dabigatran. This is
because parenteral anticoagulants are used only for inpa-
tients. Audit of external prescriptions for ambulant pa-
tients was performed by community pharmacists (Fig. 1)
mainly using information obtained by questioning
patients. All audit inquiries regarding the original pre-
scriptions were fed back to the responsible physicians
and revisions were made where appropriate.
In the present study, we retrospectively re-audited all
first-time dabigatran prescriptions that had passed the
original routine audit performed and investigated the
incidence of inappropriate prescriptions (Fig. 1). The
incidence of inappropriate prescriptions outcome were
compared between inpatients and ambulant patients.
The protocol of the present study was reviewed and ap-
proved by the institutional review board of the KIH be-
fore the study was begun (#15-2014). The present study
was conducted in compliance with the Declaration of
Helsinki and the guideline for the collection, storage
and handling of personal information of patients for
healthcare professionals issued by the Ministry of Health,
Labour and Welfare, Japan [9].
Renal function of patients was assessed by creatinine
clearance (CLcr) according to the recommendation in
the prescribing information, whenever possible. eGFR
was used as an alternative when body weight of a patient
was unavailable. For inpatients, we judged that physi-
cians had considered renal function of patients when
they measured serum creatinine concentrations within
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Table 1 An audit checklist for dabigatran prescription
Descriptions in prescribing information Criteria
Indication • Prevention of strokes and systemic thromboembolic complications in patients
with non-valvular atrial fibrillation
Contraindications • Severe renal dysfunction (CLcr < 30 mL/min or eGFR < 30 mL/min/1.73 m2a)
• Active bleeding or hemorrhagic diathesis
• Clinical complications associated with high-risk of bleeding (cerebral hemorrhage) within 6 months
• Concomitant indwelling of spinal or epidural catheter
• Concomitant oral administration of itraconazole
• History of serious hypersensitivity reaction to Prazaxa®
Instruction of dose reduction
(300 mg/day to 220 mg/day)
• Moderate renal dysfunction (CLcr 30–50 mL/min or eGFR 30–50 mL/min/1.73 m2a)
• Concomitant oral administration of P-glycoprotein inhibitorsb
• Age ≥ 70 years
• Previous history of gastrointestinal bleeding
Instruction for timing of initiating dabigatran
therapy after withdrawal of warfarin
• Dabigatran should be started after PT-INR decreases < 2.0
CLcr creatinine clearance
aAccording to the prescribing information of Prazaxa® [1] CLcr is recommended for evaluating renal function, but eGFR was used as an alternative when body
weight was unavailable
bVerapamil, amiodarone, quinidine, tacrolimus, cyclosporine, ritonavir, nelfinavir, saquinavir and others
Fig. 1 Design of the present study
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one week before they initiated dabigatran therapy. For
ambulant patients, we adopted a less rigorous criterion.
We judged that physicians had considered renal function
when serum creatinine concentrations measured within
three months were available at the initiation of dabigatran
therapy. When no serum creatinine data were available
within the respective periods, we judged that the drug
was prescribed without considering renal function and
therefore was inappropriate.
Using EMR, we checked all concomitant medications.
We also investigated past medical history of gastrointes-
tinal bleeding and upper gastrointestinal ulcer for each
patient through EMR. While we did not adopt as an out-
come measure, we searched for newly developed bleeding
or thromboembolic event up to 1 year after the initiation
of dabigatran therapy. When patients stopped taking
dabigatran or visiting the ambulant clinic of KIH for any
reason, their data collected until the last observation
were included in the analysis. When patients were re-
ferred to the two KIH-affiliated ambulant clinics located
in Hachioji city, their data collected in those clinics were
included in the analysis. We evaluated the presence or
absence of bleeding and its severity according to the
criteria employed in the RE-LY study [10].
Statistical analysis
Statistical analyses of the patients’ characteristics, num-
bers of concomitant medication and incidence of in-
appropriate prescriptions were performed using either
Fisher’s exact test or the Student’s t-test for continuous
variables and the Chi-squared test was for gender ratio.
Odds ratios and 95% confidence intervals were calcu-
lated for the prevalence data. A p value less than 0.05
was considered to be statistically significant. The JMP
software (version 11.0 SAS Institute Inc., NC, USA)
was employed for statistical analyses.
Results
We retrieved the demographic and clinical data of 137
ambulant patients and 101 inpatients who were pre-
scribed dabigatran for the first time during the study
period at KIH (Fig. 1). Six ambulant patients and 4 inpa-
tients were excluded from analysis because their drug
history revealed that they had taken dabigatran before
admission or received dabigatran previously in other
medical institutions with documented doses of dabiga-
tran in the medical history. As a result, 131 ambulant
patients and 97 inpatients were considered eligible for
the re-audit analysis (Table 2). The median duration of
the observation period for clinical events after the com-
mencement of dabigatran was 197 days (range: 3–365
days). Seven ambulant patients who never revisited KIH
after the start of dabigatran therapy were included in the
analysis of appropriateness of dabigatran prescription
but excluded from the outcome analysis.
There were no significant differences between inpatients
and ambulant patients with respect to demographic and
biochemical data except for serum aspartate aminotrans-
ferase (AST) level and renal function (Table 2). While the
mean serum AST level in the ambulant patients was sig-
nificantly (p < 0.05) lower than that in inpatients, both
values were within the respective normal ranges. While
the ambulant patients had significantly (p < 0.05) lower
eGFR than the inpatients (64 ± 14 vs. 69 ± 18 mL/min/
1.73 m2, respectively), the small differences between
groups (5 mL/min/1.73 m2) would have been clinically
insignificant (Table 2). There was a good correlation
between eGFR and CLcr (r = 0.72, p < 0.001, data are
not shown) in patients whose body weights were avail-
able (50 ambulant patients and 80 inpatients). Because
of inherent limitations of the retrospective study design,
some demographic and biochemical data were incom-
plete. For instance, heights were not available for 84
Table 2 Characteristics of ambulatory patients and inpatients whose prescriptions of dabigatran were analyzed
Variables Ambulant patients (n = 131) Inpatients (n = 97) P value
Age (years) 71 ± 9 70 ± 12 NS
Male (%) 96 (73) 64 (66) NS
ALT (IU/L) 22 ± 12 26 ± 22 NS
AST (IU/L) 25 ± 11 29 ± 17 0.01
ALP (IU/L) 242 ± 76 238 ± 80 NS
Serum creatinine (mg/dL) 1.2 ± 0.2 [130] 1.0 ± 0.3 0.02
eGFR (mL/min/1.73 m2) 64 ± 14 [130] 69 ± 18 0.03
Height (cm) 162 ± 10 [47] 161 ± 10 [77] NS
Weight (kg) 61 ± 12 [50] 60 ± 13 [80] NS
Body surface area (m2) 1.6 ± 0.2 [47] 1.6 ± 0.2 [77] NS
Numbers of concomitant medication 4.6 ± 3.5 4.2 ± 3.2 NS
Data are expressed as means ± SD. Numbers of patients whose data were available are given in brackets. Data without bracket indicate that data were available
from all patients in each group. Statistical analyses were performed with the Student’s t-test for continuous variables and with the Chi-squared test for gender ratio
Abbreviations: ALT alanine aminotranferase, AST aspartate aminotransferase, ALP alkaline phosphatase, NS not significant
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out of 131 ambulant patients (64%) and 20 out of 97
inpatients (21%). Body weights were not available in 81
(62%) and 17 (18%) of ambulant patients and inpa-
tients, respectively.
Among the 228 patients who were prescribed dabigatran
for the first time during the study period, re-audit of the
prescriptions showed that the prescriptions in 174 patients
(76%) were appropriate because they complied with all the
instructions in the prescribing information. When compar-
ing the prescriptions for ambulant patients and inpatients,
a significantly (p < 0.001) greater proportion of ambulant
patients had inappropriate dabigatran prescriptions com-
pared to inpatients: 33% vs 11% [odds ratio (OR): 3.8, 95%
confidence interval (CI): 1.8–7.9; Table 3].
Detailed results for the re-audit of the dabigatran
prescriptions are given in Table 3. There were no pre-
scriptions for unapproved indication. There were 2 cases
of violation of contraindication: 2 ambulant patients
with CLcr <30 mL/min were prescribed dabigatran. No
violation of contraindication was observed in inpatients.
Verapamil, a strong inhibitor of P-glycoprotein, was
co-administered with dabigatran without reducing the
dose of dabigatran in 7 and 3 ambulant and inpatients,
respectively. According to the prescribing information, a
lower dose of dabigatran (110 mg twice daily) is recom-
mended when verapamil is co-administered [1]. Five am-
bulant patients and one inpatient were prescribed lower
doses of the drug than those recommended: 2 ambulant
patients ≥ 70 years were underdosed at 75 mg once daily
or 75 mg b.i.d. instead of 110 mg b.i.d. as recommended
by the prescribing information and 3 ambulant patients
< 70 years were underdosed at 110 mg b.i.d. instead of
150 mg b.i.d. as recommended by the prescribing infor-
mation. In addition, one inpatient ≥ 70 years was under-
dosed at 75 mg b.i.d. instead of 110 mg b.i.d (Table 3).
No appreciable reasons were found in their EMR. While
the incidence of the violation of the timing for the com-
mencement of dabigatran therapy by referring to the
PT-INR of < 2.0 for the ambulant patients (26%, 14 out
of 54 patients), was apparently greater than that for the
inpatients (5%, 1 out of 21 patients), the difference did
not reach the statistically significant level (p = 0.053).
Table 3 Comparisons of the frequencies of inappropriate prescriptions of dabigatran between ambulant patients and inpatients





Overall (%) 43 (33) 11 (11) <0.001
Unauthorized indication 0 0 NA
Violation of contraindications
eGFR < 30 mL/min/1.73 m2 0 [0] 0 [0] NA
CLCr < 30 mL/min 2 [50] 0 [80] 0.15
Concomitant use with oral itraconazole 0 0 NA
Active bleeding or hemorrhagic diathesis 0 0 NA
History of complications associated with high-risk of bleeding
(cerebral hemorrhage) in the latest 6 months
0 0 NA
Concomitant dwelling of spinal or epidural catheters 0 0 NA
History of serious hypersensitivity reaction to Prazaxa® 0 0 NA
Inappropriate dose selection in reference to age
Overdose for patients≥ 70 years (%) 14/77 (18) 2/56 (4) <0.05
Underdose for patients≥ 70 years (%) 2/77 (3) 1/56 (2) NS
Overdose for patients < 70 years (%) 0/54 (0) 0/41 (0) NA
Underdose for patients < 70 years (%) 3/54 (6) 0/41 (0) NS
Non-compliance with the recommendations for dose reduction
eGFR from 30 to 50 mL/min/1.73 m2 (%) 2/22 (9) 1/10 (10) NS
CLcr from 30 to 50 mL/min 0/11 (0) 1/15 (7) NS
Past medical history of gastrointestinal bleeding (%) 1/5 (20) 3/5 (60) NS
Concomitant use of verapamil (%) 7/10 (70) 3/7 (43) NS
No assessment of renal function (%) 1/131 (1) 0/97 (0) NS
PT-INR < 2.0 when dabigatran was started after discontinuation of warfarin 14/54 (26) 1/21 (5) 0.053
The figures in brackets are numbers of eligible patients
Four cases (3 ambulant patients and 1 inpatient, respectively) had more than one violations of the instructions given in the prescribing information.
Statistical analyses were performed with Fisher’s exact test
NA not applicable, NS not significant
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The EMR documented bleeding events in 9 of 124
ambulant patients (7.3%) and in 8 of 97 inpatients
(8.2%), with no significant difference in incidence be-
tween two groups (OR 0.9, 95% CI 0.3–2.3). None of
the bleeding events were judged to be major according
to the criteria adopted from the RE-LY study [10]. Cere-
bral infarction occurred in 1 of 124 ambulant patients
(0.8%) and in 1 of 97 inpatients (1.0%), with no signifi-
cant difference in incidence between two groups (OR
0.8, 95% CI 0.1–13). Scrutinizing their prescriptions of
dabigatran, we considered that the prescription for the
ambulant patient who developed cerebral infarction
was appropriate, but that for the inpatient was inappro-
priate because he received dabigatran at 150 mg b.i.d.
even though he had a past medical history of gastro-
intestinal bleeding. According to the prescribing infor-
mation, he should have received the drug at 110 mg
b.i.d. During the observation period, dose reduction of
dabigatran was undertaken in 13 patients, two of whom
were due to minor bleeding episodes while the others
for no appreciable reasons in EMR.
Discussion
As separation of dispensary from medical practice pro-
gresses in Japan, hospital pharmacists are getting in-
volved in pharmaceutical care of patients in the wards
than in dispensary for ambulant patients [11]. In the
present study, we demonstrated that the frequency of in-
appropriate prescriptions of dabigatran for inpatients
(11%) was significantly (p < 0.001) lower than that for
ambulant patients (33%). Prescriptions for inpatients
were audited by hospital pharmacists using abundant in-
formation available from EMR, whereas prescriptions for
ambulant patients were audited by community pharma-
cists based on limited information mainly by questioning
patients. The difference in available medical information
between the two groups would have contributed largely
to that in frequency of inappropriate prescriptions, pro-
vided that hospital and community pharmacists were
comparable in audit competency. Thus, there is certainly
advantage for hospital pharmacists to undertake audit of
prescriptions for external prescriptions particularly for
drugs that had contraindication or instruction of dose
reduction according to renal function, age and concomi-
tant medications. According to the annual survey of the
service framework of hospital pharmacists in 2015 [11],
prescription audit for ambulant patients was performed
by hospital pharmacists in 46% of the hospitals surveyed
in Japan.
Regarding audit competency in terms of dose adjust-
ment according to patient’s age, there was a significantly
higher frequency of inappropriate prescription [18%
(14/77)] for ambulant patients aged 70 years or older:
they should have been dispensed the drug at a reduced
dose of 110 mg b.i.d., instead of 150 mg b.i.d., accord-
ing to the prescribing information. On the contrary,
only 4% (2/56) of inpatients in the same age group were
given the drug at 150 mg b.i.d. (p < 0.05, Table 3). While
we cannot categorically attribute the observed differ-
ence to that in audit competency between hospital and
community pharmacists, it may be prudent to provide
basic demographic information to community pharma-
cists for dabigatran and others of which audit needs
such information.
Because an active metabolite of dabigatran etexilate,
dabigatran, is eliminated almost exclusively in urine [1],
renal function of patients is an important variable for
individualizing dosage of the drug. In the prescribing
information of dabigatran etexilate it is recommended
that renal function of patients be assessed by CLcr
(mL/min/body) [1]. Two ambulant patients (1.5%) with
CLcr <30 mL/min were given reduced doses of dabiga-
tran (75 mg b.i.d. or 110 mg b.i.d.) despite that dabiga-
tran was contraindicated for these patients. One was a
97-year male weighing 54 kg and the other was a 88-
year female weighing 36 kg: their renal function was 38
and 51 mL/min/1.73 m2 in eGFR and 24 and 28 mL/
min in CLcr, respectively. In retrospect, the physicians
and community pharmacists should have referred to
their CLcr values. It is well known that eGFR (mL/min/
1.73 m2) of a patient having lower body weight is
tended to overestimate CLcr (mL/min/body). Because
the 97-year male patient weighted 54 kg, the reason
why his eGFR was greater than CLcr would have been
attributed to the discordance of the Cockcroft-Gault
and MDRD formulas. In contrast, no inpatients with
CLcr <30 mL/min were prescribed dabigatran, probably
due to the competent audit by pharmacists. Regarding
the prescriptions for patients with moderately reduced
renal function (CLcr 30–50 mL/min), a greater propor-
tion of inpatients (7%) received dabigatran without
appropriate dosage reduction compared to ambulant
patients (0%). However, there is no significant differ-
ence between the two groups.
To our knowledge, seven previous studies [12–18] re-
ported the frequency of potentially inappropriate dabi-
gatran prescriptions in real-world practice in different
countries (Table 4). Direct comparisons of the data ob-
tained from the present study and those obtained from
previous studies would be difficult, since all studies
employed different criteria for inappropriate prescrip-
tions. Nevertheless, the four studies [12–14, 18] that
adopted criteria similar to those in the present study
reported frequencies of potentially inappropriate dabi-
gatran prescriptions (from 2.0 to 31.2%) comparable to
that observed for inpatients in the present study (11%).
In contrast, three other studies [15–17] reported sub-
stantially higher values (from 34.1 to 51.1%) than the
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present study. Two of these three studies adopted the
medication appropriate index (MAI) [16, 17] for judg-
ing appropriateness of prescription. The MAI includes
10 criteria for judging appropriateness of prescription:
indication, choice, dosage, modalities and practicability
of administration, drug-drug interactions, drug-disease
interactions, duplication, duration and cost-effectiveness,
which are assessed over the whole treatment period. The
remaining study [15] judged appropriateness of dabigatran
prescription solely by co-administration of medications
with the potential to increase bleeding risk (non-steroidal
anti-inflammatory drugs, selective serotonin re-uptake in-
hibitors, oral corticosteroids) or P-glycoprotein inhibitors
(systemic azole antifungals, macrolide antibiotics, HIV
protease inhibitors, cyclosporine, dronedarone, tacroli-
mus, verapamil, amiodarone and quinidine). Obviously,
the apparent discrepancies in frequency of inappropri-
ate dabigatran prescriptions between the present study
and these three studies would be attributable to the
differences in the criteria used to judge inappropriate
prescription of this drug.
While there are abundant reports on the frequency of
dispensing error, only a few studies reported audit failure
rates of pharmacists. Beex-Oosterhuis et al. [19] under-
took a prospective collaborative study in 57 medical in-
stitutes to investigate the audit failure by intentionally
mixing potentially inappropriate medications in routine
prescriptions. Their study revealed that the pharmacists’
audit on prescriptions may overlook on average 41%
of potentially inappropriate medications. In addition,
Kuo et al. reported [20] that clinical pharmacists in
USA identified a total of 779 cases of various types of
medication errors and 58% of the errors actually
reached the patients. In the present study, we found
that 11% of prescriptions for dabigatran issued to in-
patients in our hospital were considered inappropriate
(11 of 97 inpatients). Regrettably, we were unable to
determine conclusively whether an inappropriate pre-
scription for a given inpatient was attributable either
to a physicians’ error that was overlooked by pharma-
cists’ audit (i.e., audit failure) or to physicians’ non-
acceptance of pharmacists’ inquiry about inappropriate
doses of the drug.
The present study has several limitations that are in-
herent to a retrospective design. First, there were miss-
ing data and data collection was incomplete (Table 2).
Second, comparison of the frequency of inappropriate
prescriptions between ambulant patients and inpatients
might have been biased, because no randomization of
patients was implemented for allocating patients to the
two groups. Because the present study was performed
in a single hospital, its external validity is to be exam-
ined in a multi-center collaborative study with a larger
number of patients. In addition, the present study is far
underpowered (n = 228) for addressing any potential
implications of pharmacists’ audit on the prevalence of
thromboembolic or bleeding events in patients receiv-
ing dabigatran over a rather short observation period
(the median interval of 197 days).
Conclusion
Pharmacists’ audit of first-time prescriptions of dabiga-
tran for inpatients using EMR may achieve better per-
formance in eliminating inappropriate prescriptions
compared to audit for ambulant patients who receive
external prescriptions.
Table 4 Summary of previous and present studies investigating inappropriate prescriptions of dabigatran







Armbruster et al. [12] USA R 458 I 16.6 14.4 -
Simon et al. [13] USA R 395 A 2 16 No serum creatinine levels were available within
1 week before and after the time of dabigatran
initiation in 37% of patients.
Kimmons et al. [14] USA R 160 I 9a, 10b 3.8 aIndication and bdose. Only 61% of patients were
newly initiated on dabigatran during the study period.
McDonald et al. [15] USA, Canada
and Australia
R 16,000 A 34.1–51.1 27.3–43.7 PIM was judged solely by co-administration of
medicines potentially increase bleeding riskc
Larock et al. [16] Belgium P 69 I/A 49 14.7 MAI was used for assessing PIM
Basaran et al. [17] Turkey P 148 A 47 NA MAI was used for assessing PIM
Chowdhry et al. [18] Canada R 109 I 31.2 NA -
The present study Japan R 228 I/A I (11)
vs. A (33)
7.7 Inappropriate prescription was judged according to
the descriptions in prescribing information
R retrospective chart review, P prospective study, I inpatients, A ambulant patients, MAI medication appropriate index, MAI is a tool designed to measure
appropriateness of prescribing for people aged 65 years and older using 10 criteria comprising indication, choice, dosage, modalities and practicability of
administration, drug-drug interaction and cost-effectiveness. [16, 17], IM inappropriate medication PIM potentially inappropriate medication, NA not available
cselective serotonin reuptake inhibitor, non-steroidal anti-inflammatory drug, oral corticosteroids, systemic azole antifungals, macrolide antibiotics, HIV protease
inhibitors, cyclosporine, dronedarone, tacrolimus, verapamil, amiodarone and quinidine
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